Biomarkers in the evolution of multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Biomarker Discovery

Background:

• Nonimaging biomarkers are crucial for diagnosing and managing multiple sclerosis (MS).
• Established biomarkers include oligoclonal IgG bands for diagnosis and AQP4 antibodies for neuromyelitis optica spectrum disorder.
• Current limitations exist in personalized disease progression tracking and predicting treatment response.

Purpose of the Study:

• To review the current landscape of nonimaging biomarkers in multiple sclerosis (MS) and related disorders.
• To highlight the diagnostic and prognostic value of existing biomarkers.
• To identify unmet needs in biomarker development for MS progression and therapy monitoring.

Main Methods:

• Literature review of nonimaging biomarkers in multiple sclerosis and related neurological conditions.
• Analysis of diagnostic and prognostic utility of biomarkers such as oligoclonal IgG bands, AQP4 antibodies, and MOG antibodies.
• Evaluation of biomarkers for monitoring treatment efficacy and predicting adverse events.

Main Results:

• Oligoclonal IgG bands in cerebrospinal fluid are key diagnostic markers and negative predictors of MS progression.
• AQP4 antibodies are essential for diagnosing neuromyelitis optica spectrum disorder.
• Neutralizing antibodies against therapies like IFN-β and natalizumab impact treatment efficacy.
• The anti-John Cunningham virus antibody index shows potential for predicting progressive multifocal leukoencephalopathy risk.

Conclusions:

• Nonimaging biomarkers play a vital role in the differential diagnosis, progression evaluation, and therapy monitoring of MS.
• Further research is needed to develop individualized biomarkers for precise disease tracking and treatment optimization.
• Established biomarkers provide critical diagnostic information, but gaps remain in predicting long-term outcomes and therapeutic responses.